Risk of venous thrombosis in patients with pancreatic adenocarcinoma

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 12, 2007, Pages 1139-1142

  Mitry, Emmanuel ^a,b,c   Taleb Fayad, Raffic ^a   Deschamps, Antoine ^a,b   Mansencal, Nicolas ^a,b   Lepère, Céline ^a   Declety, Gilles ^a   Lièvre, Astrid ^a,b   Vaillant, Jean Nicolas ^a   Lesur, Gilles ^a   Cramer, Élisabeth ^a,b   Dubourg, Olivier ^a,b   Rougier, Philippe ^a,b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c Ambroise Paré Teaching Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; DEEP VEIN THROMBOSIS; FEMALE; HIGH RISK PATIENT; HISTOLOGY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOSIS PREVENTION;

EID: 38049115496     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)78352-5     Document Type: Article

References (16)

1. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004;5:655-63.
2. Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer 2006;42:410-4.
3. Lensing AW, Prandoni P, Brandjes D, Huisman PM, Vigo M, Tomasella G, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med 1989;320:342-5.
4. Qanadli SD, Hajjam ME, Mesurolle B, Barre O, Bruckert F, Joseph T, et al. Pulmonary embolism detection: prospective evaluation of dual-section helical CT versus selective pulmonary arteriography in 157 patients. Radiology 2000;217:447-55.
5. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003;72:43-52.
6. De Cicco M.The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004;50:187-96.
7. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999;25:137-45.
8. Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost 1999;25:167-72.
9. Falanga A.Thrombophilia in cancer. Semin Thromb Hemost 2005;31:104-10.
10. Pihusch R, Danzl G, Scholz M, Harich D, Pihusch M, Lohse P, et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 2002;94:3120-6.
11. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-22.
12. Ambrus JL, Ambrus CM, Pickern J, Soldes S, Bross I. Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis. J Med 1975;6:433-58.
13. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-91.
14. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-9.
15. Karthaus M, Kretzschmar A, Kroning H, Biakhov M, Irwin D, Marschner N, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289-96.
16. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063-9.